See more : Denka Company Limited (4061.T) Income Statement Analysis – Financial Results
Complete financial analysis of Alpha Cognition Inc. (ACOGF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alpha Cognition Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- BKM Industries Limited (BKMINDST.BO) Income Statement Analysis – Financial Results
- Invesque Inc. (MHIVF) Income Statement Analysis – Financial Results
- HORNBACH Baumarkt AG (0ENN.L) Income Statement Analysis – Financial Results
- H.B. Fuller Company (FUL) Income Statement Analysis – Financial Results
- Acuity Brands, Inc. (AYI) Income Statement Analysis – Financial Results
Alpha Cognition Inc. (ACOGF)
About Alpha Cognition Inc.
Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; and ALPHA-0602, a gene therapy for the treatment of ALS. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 86.03K | 87.32K | 89.09K | 85.75K | 0.00 | 0.00 |
| Gross Profit | -86.03K | -87.32K | -89.09K | -85.75K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.92M | 8.82M | 7.97M | 4.67M | 3.56M | 0.00 |
| General & Administrative | 4.50M | 4.53M | 3.40M | 950.71K | 391.47K | 0.00 |
| Selling & Marketing | 19.79K | 31.73K | 103.25K | 0.00 | 98.31K | 0.00 |
| SG&A | 4.71M | 4.56M | 3.51M | 950.71K | 1.52M | 32.46K |
| Other Expenses | 0.00 | 0.00 | -1.40M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.71M | 13.47M | 11.57M | 5.71M | 5.47M | 32.46K |
| Cost & Expenses | 9.71M | 13.47M | 11.57M | 5.71M | 5.47M | 32.46K |
| Interest Income | 6.93K | 1.93K | 2.07K | 22.59K | 8.13K | 0.00 |
| Interest Expense | 68.95K | 172.88K | 528.16K | 770.37K | 0.00 | 0.00 |
| Depreciation & Amortization | 84.48K | 87.32K | 89.09K | 85.75K | 79.04K | 0.00 |
| EBITDA | -9.71M | -13.13M | -11.03M | -5.69M | -5.08M | -32.46K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.71M | -13.46M | -11.57M | -5.68M | -5.16M | -32.46K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.07M | 1.01M | -8.51M | -96.58K | -1.52M | 0.00 |
| Income Before Tax | -13.77M | -12.11M | -19.55M | -5.78M | -6.61M | -32.46K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 172.88K | 528.16K | 770.37K | -78.45 | 0.00 |
| Net Income | -13.77M | -12.11M | -19.55M | -5.78M | -6.61M | -32.46K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.15 | -0.18 | -0.37 | -0.96 | -0.21 | -0.03 |
| EPS Diluted | -0.15 | -0.18 | -0.37 | -0.96 | -0.21 | -0.03 |
| Weighted Avg Shares Out | 94.36M | 67.97M | 53.33M | 6.02M | 31.46M | 1.19M |
| Weighted Avg Shares Out (Dil) | 94.36M | 67.97M | 53.33M | 6.02M | 31.46M | 1.19M |
Alpha Cognition Announces Initial Closing of Private Placement and Pricing for Continuation of the Offering
Alpha Cognition Announces Second Quarter and Six Months Ended 2023 Results and Provides Corporate Update
Alpha Cognition Receives Notice of Allowance for U.S. Patent Application covering use of ALPHA-1062 for Mild to Moderate Alzheimer's Disease
Alpha Cognition to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & 1x1 Meetings on Thursday, April 27, 2023
Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease
Source: https://incomestatements.info
Category: Stock Reports